Cencora, Inc. $COR Shares Bought by Swiss National Bank

Swiss National Bank boosted its holdings in shares of Cencora, Inc. (NYSE:COR) by 13.7% in the 2nd quarter, Holdings Channel reports. The firm owned 557,600 shares of the company’s stock after buying an additional 67,000 shares during the period. Swiss National Bank’s holdings in Cencora were worth $167,196,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Private Advisor Group LLC boosted its position in Cencora by 9.2% during the 1st quarter. Private Advisor Group LLC now owns 6,796 shares of the company’s stock worth $1,890,000 after acquiring an additional 572 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Cencora in the 1st quarter valued at about $753,000. Pinnacle Associates Ltd. lifted its position in shares of Cencora by 67.9% in the first quarter. Pinnacle Associates Ltd. now owns 2,817 shares of the company’s stock worth $783,000 after purchasing an additional 1,139 shares in the last quarter. SFE Investment Counsel acquired a new stake in shares of Cencora during the first quarter worth approximately $234,000. Finally, Advisor OS LLC boosted its holdings in shares of Cencora by 28.4% during the first quarter. Advisor OS LLC now owns 2,881 shares of the company’s stock worth $801,000 after purchasing an additional 638 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Up 1.0%

Cencora stock opened at $365.56 on Friday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $369.38. The firm’s fifty day simple moving average is $327.70 and its 200-day simple moving average is $304.57. The company has a market capitalization of $70.87 billion, a P/E ratio of 37.61, a P/E/G ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the prior year, the company posted $3.34 earnings per share. Cencora’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is currently 30.19%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on COR shares. JPMorgan Chase & Co. increased their target price on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. UBS Group increased their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Robert W. Baird upped their target price on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $371.09.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 46,640 shares of company stock worth $14,099,338 over the last three months. 10.80% of the stock is owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.